Why NAFDAC Recalled Deekins Amoxycillin Batch

The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the recall of a specific batch of Deekins Amoxycillin 500mg Capsules, manufactured by Ecomed Pharma Ltd and marketed by DevineKings Pharmaceutical Ltd. The affected batch, identified as lot number 4C639001, is being withdrawn following reports of serious adverse drug reactions.

Why Was the Product Recalled?

According to NAFDAC, the recall was triggered by hospital reports of three cases of serious adverse reactions among patients administered the drug. These reactions prompted Ecomed Pharma Ltd, the manufacturer, to take action in collaboration with NAFDAC to remove the batch from the market.

NAFDAC warns that adverse drug reactions can be severe and potentially life-threatening. Such reactions, the agency noted, “may require hospitalization, prolong existing hospitalization, or result in significant disability or even death in fatal cases.”

What Is Deekins Amoxycillin?

Deekins Amoxycillin 500mg Capsule is a penicillin-based antibiotic widely used to treat bacterial infections. It is prescribed for conditions such as tonsillitis, bronchitis, pneumonia, sinusitis, and bacterial infections affecting the ear, nose, throat, skin, or urinary tract.

While effective for treating these conditions, antibiotics like amoxicillin must be manufactured and handled with utmost care to ensure their safety.

NAFDAC underscores the importance of obtaining medications from authorized suppliers and checking their authenticity.

“All medical products must be obtained from authorized/licensed suppliers,” the agency cautioned, adding that the physical condition of the product should be inspected before use.

Also Read: Why NAFDAC Wants Nigerians to Stop Using Nivea Black & White Invisible Roll-On

What Should Consumers and Health Professionals Do?

NAFDAC has issued clear guidelines for those who may have the affected product in their possession. Distributors and healthcare providers are urged to discontinue the sale, distribution, or administration of the batch in question. Patients are advised to stop using the product immediately and return any stock to the nearest NAFDAC office.

“If you have used this product, or someone you know has used it, and suffered any adverse reaction, you are advised to seek immediate medical attention from a qualified healthcare professional,” NAFDAC advised.

Healthcare professionals and consumers are encouraged to report cases of adverse reactions or suspected substandard medicines to NAFDAC through multiple channels. Reports can be made via the agency’s toll-free number (0800-162-3322), email ([email protected]), or the Med-safety app, which is available for download on Android and iOS devices.

NAFDAC also called for vigilance within the supply chain to prevent the distribution or use of the affected batch. The agency stresses that “the authenticity and physical condition of medicines must be carefully checked” to avoid risks associated with substandard or falsified drugs.